Tolvaptan efficacy was assessed among younger adults 18-35 years with autosomal dominant polycystic kidney disease (ADPKD), who are at high risk for progression.
The prevalence of chronic kidney disease is rising globally, with millions of individuals affected. Factors such as renal illnesses, diabetes, and hypertension contribute to the growing incidence, ...